Global Leading Market Research Publisher QYResearch announces the release of its latest report “Anethol Trithione Tablets – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Anethol Trithione Tablets market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Anethol Trithione Tablets was estimated to be worth US$ 304 million in 2025 and is projected to reach US$ 380 million, growing at a CAGR of 3.3% from 2026 to 2032.
Anethol Trithione tablets are pharmaceutical formulations primarily used for liver protection and treatment of various liver disorders, including chronic hepatitis and cholestasis. These tablets contain anethol trithione, a sulfur-containing compound that promotes bile secretion and exhibits antioxidant properties, helping to improve liver function and detoxification. Widely prescribed in many countries, anethol trithione tablets are valued for their effectiveness in supporting liver health and alleviating symptoms associated with impaired bile flow. They are typically administered orally, with dosage and treatment duration tailored to the patient’s specific condition. In 2024, global anethol trithione tablets sales volume reached approximately 2114.3 million pcs , with an average global market price of around US$ 0.14 per pc.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6095538/anethol-trithione-tablets
1. Industry Pain Points and the Shift Toward Hepatoprotective Agents
Chronic liver diseases (hepatitis B/C, non-alcoholic fatty liver disease, cholestasis) affect over 1.5 billion people globally. Conventional treatments (antivirals, immunosuppressants) may not address bile flow impairment or oxidative stress. Anethol trithione tablets address this with a hepatoprotective therapy that acts as a cholagogue agent (promotes bile secretion) and antioxidant (reduces oxidative liver damage). For hepatologists and gastroenterologists, anethol trithione provides supportive therapy for chronic hepatitis, cholestasis, and dry eyes (Sjögren’s syndrome).
2. Market Size, Production Volume, and Growth Trajectory (2024–2032)
According to QYResearch, the global anethol trithione tablets market was valued at US$ 304 million in 2025 and is projected to reach US$ 380 million by 2032, growing at a CAGR of 3.3%. In 2024, global sales volume reached approximately 2.11 billion tablets with an average selling price of US$ 0.14 per tablet. Market growth is driven by three factors: increasing prevalence of chronic liver diseases (NAFLD, hepatitis), aging population (cholestasis), and OTC availability in some markets (self-medication for liver support).
3. Six-Month Industry Update (October 2025–March 2026)
Recent market intelligence reveals four notable developments:
- NAFLD awareness: Rising non-alcoholic fatty liver disease (NAFLD) prevalence (25% globally) drove 10% increase in hepatoprotective supplement demand. NAFLD segment grew 12% year-over-year.
- OTC expansion: Anethol trithione tablets gained OTC status in several Asian markets (China, Vietnam, Indonesia), enabling direct consumer access. OTC segment grew 15% in 2025.
- Dry eye indication: Anethol trithione (mucolytic, tear film stabilization) for dry eyes (Sjögren’s, evaporative dry eye) gained 8% market share in ophthalmology.
- Chinese supplier dominance: Sichuan Aupone Pharmaceutical, Anhui Pioneer Pharmaceutical, and CCP captured 60%+ of global market, offering cost-competitive generics (20-30% below Western pricing).
4. Competitive Landscape and Key Suppliers
The market includes global ophthalmology leaders and Chinese manufacturers:
- Pharmesis (Singapore), Sichuan Aupone Pharmaceutical (China), CCP (China), Anhui Pioneer Pharmaceutical (China), Norwell (US), Bausch & Lomb (US – dry eye indication), Conquer (China).
Competition centers on three axes: price per tablet, OTC vs. prescription status, and combination formulations.
5. Segment-by-Segment Analysis: Type and Application
By Regulatory Status
- OTC: Largest segment (~60% of market). Self-medication for liver support, digestive health. Fastest-growing segment (CAGR 4%).
- Prescription Drug: (~40% of market). For chronic hepatitis, cholestasis, physician-directed therapy.
By Application
- Digestive Diseases: Largest segment (~80% of market). Chronic hepatitis, cholestasis, NAFLD, drug-induced liver injury.
- Dry Eyes: (~20% of market). Sjögren’s syndrome, evaporative dry eye. Fastest-growing segment (CAGR 5%).
User case – Chronic hepatitis B (supportive therapy) : A patient with chronic hepatitis B (on tenofovir) had persistent fatigue and elevated liver enzymes (ALT 80 U/L). Anethol trithione tablets (25 mg TID) added as hepatoprotective therapy. After 3 months, ALT normalized (40 U/L). Fatigue resolved. Liver stiffness (FibroScan) improved from 8.5 kPa to 6.2 kPa. Anethol trithione used as adjunctive therapy to antiviral treatment.
6. Exclusive Insight: Anethol Trithione Mechanism and Clinical Applications
| Mechanism | Effect | Clinical Application |
|---|---|---|
| Choleretic (bile secretion) | Increased bile flow, reduced cholestasis | Intrahepatic cholestasis, drug-induced liver injury |
| Antioxidant (glutathione sparing) | Reduced oxidative stress, lipid peroxidation | NAFLD, alcoholic liver disease |
| Mucolytic | Reduced mucus viscosity | Chronic bronchitis, dry eyes (tear film stabilization) |
| Anti-inflammatory | Reduced cytokine production | Hepatitis, cholangitis |
| Cytochrome P450 modulation | Improved drug metabolism | Adjunctive therapy |
Technical challenge: Bioavailability and dosing optimization. Anethol trithione has short half-life (2-4 hours), requiring TID dosing (25-50 mg). Sustained-release formulations in development aim for BID or once-daily dosing.
User case – Dry eyes (Sjögren’s syndrome) : A patient with Sjögren’s syndrome (severe dry eyes) failed artificial tears and cyclosporine eye drops. Oral anethol trithione tablets (25 mg TID) added. After 8 weeks, tear break-up time (TBUT) improved from 3 seconds to 8 seconds. Ocular Surface Disease Index (OSDI) decreased from 65 to 35. Patient reported reduced eye dryness and irritation.
7. Regional Outlook and Strategic Recommendations
- Asia-Pacific: Largest and fastest-growing region (65% share, CAGR 4%). China (Sichuan Aupone, CCP, Anhui Pioneer, Conquer), Singapore (Pharmesis), Vietnam, Indonesia. High hepatitis B prevalence, OTC availability, generic manufacturing.
- North America: Second-largest (20% share, CAGR 3%). US (Bausch & Lomb, Norwell). Dry eye indication (off-label), hepatoprotective supplement market.
- Europe: Stable market (10% share, CAGR 2.5%). Limited OTC availability, prescription-only in most countries.
- Rest of World: Latin America, Middle East. Smaller but growing.
8. Conclusion
The anethol trithione tablets market is positioned for steady growth through 2032, driven by chronic liver disease prevalence, OTC expansion, and dry eye applications. Stakeholders—from pharmaceutical manufacturers to healthcare providers—should prioritize OTC formulations for consumer access, dry eye indication for market expansion, and combination products (with silymarin, phosphatidylcholine) for enhanced hepatoprotection. By offering hepatoprotective therapy and cholagogue agent benefits, anethol trithione tablets support liver health and digestive function.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
